Interview with CEO
In brief · summary, not quotable
CEO gave interview to Proactive Investors discussing name change, Awakn acquisition and 2025 priorities.
Full announcement
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Therapeutics (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces an interview on Proactive Investors with Anthony Tennyson, CEO of the Company. The interview with Anthony Tennyson can we viewed now at https://www.proactiveinvestors.co.uk/companies/news/1064271/solvonis-therapeutics-ceo-on-name-change-awakn-acquisition-and-2025-priorities.html.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.